Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial – PubMed

This trial confirms the superiority of the combination melphalan and prednisone plus thalidomide over melphalan and prednisone alone for prolonging survival in very elderly patients with newly diagnosed myeloma. Toxicity was acceptable.

Read the full article here

Source: PubMed
Categories: Latest Headlines, Partners & KOLs
Tags:
Tweets with this article
Manni Mohyuddin
A trip down memory lane- and another great trial by the IFM group. IFM 01/01 (enrolled from 2002-06) Melphalan/pred (MP) vs MP+thalidomide (MPT) in patients aged ≥75 with MM Primary Endpoint: Overall Survival, 29 mo for MP vs 44 mo for MPT #mmsm https://t.co/PhBfc1DgBZ https://t.co/DVm2gdT1ZK

Related Articles